RxDoctor Payments Data

James Badman, MD

Family Medicine · Altamonte Springs, FLNPI 1265470405

Payments from drug & device makers

$519in general payments, 2019–2025

Across 8 payments — averaging $64.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$130
  • Alkermes, Inc.$125
  • Boehringer Ingelheim$112
  • Novartis$111
  • Abbott$24
  • AstraZeneca$12
  • plus $6 from 1 others

What the payments were for

  • Food & beverage$50297%
  • Education$173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$519 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$175,348
Medicare patients
424
Services billed
1,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide100$115,185
JardianceEmpagliflozin56$81,966
OzempicSemaglutide55$76,051
EliquisApixaban61$73,598
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$40,305
TrulicityDulaglutide32$36,467
Tresiba Flextouch U-100Insulin Degludec16$22,353
JanuviaSitagliptin Phosphate24$18,819
Testosterone50$10,716
FarxigaDapagliflozin Propanediol11$9,631
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,968
Liothyronine Sodium132$5,919
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$5,829
VyvanseLisdexamfetamine Dimesylate14$5,345
Rosuvastatin Calcium477$5,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$112$81,96656 claims
Novo NordiskOzempic$130$76,05155 claims
AstraZenecaFarxiga$12$9,63111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Altamonte Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →